FIGURE LEGENDS
Figure 1 . IFN-γ release enzyme-linked
immunospot (ELISpot) assay release for peripheral blood mononuclear
cells (PBMC) and blister fluid cells (BFC). Data is for cryogenically
stored PBMC and BFC samples from Cases 1-4 (Supplementary Table 1). A
positive result is defined by greater than or equal to 50 spot forming
units (SFU) per million cells (green dotted line). The maximum doses for
each drug were shown to not elicit responses and cell death on a healthy
control sample, using flow cytometry (7-AAD staining) or Lactate
Dehydrogenase (LDH) viability assay ([19] and Supplementary Figure
4). SMX, Sulfamethoxazole; TMP, Trimethoprim.
Figure 2. Lymphocyte composition of blood and blister samples.Donor-matched BFC and PBMC were analysed by flow cytometry. A.Graphs show percentages of total IFN-γ+ and CD3+ lymphocytes (left of
red line) among total live lymphocytes (gated as per Supplementary
Figure 1i). T cells (CD3+) (gated after exclusion of CD14 (monocytes)
and CD19 (B cells) as per Supplementary Figure 1ii) were subsequently
analysed for: CD4 and CD8 co-receptors (CD4/CD8 double-negative cells
are indicated as DN), CD45RO (memory), CD69 (activation), CD69 and CD103
co-expression (egress/tissue residency/memory), γδ T cell receptor
(TCR), binding to MR1 5-OP-RU tetramers[20, 21] (MAIT cells), or
expression of the NK receptor CD56 (NK-like T cells) (right of red
line). B. Graphs show proportions of CD4, CD8 and CD4/CD8 DN T
cells, γδ T cells, MAIT cells and CD56+ T cells amongst IFN-γ-secreting
cells, gated as per Supplementary Figure 2.